Single nucleotide polymorphisms associated with metastatic tumour antigen 1 overexpression in patients with hepatocellular carcinoma

Liver International

Volumn 32, Issue 3, 2012, Pages 457-466

  Lee, Sae Hwan ^a   Chung, Young Hwa ^b   Kim, Jeong A ^b   Lee, Danbi ^b   Jin, Young Joo ^b   Shim, Ju Hyun ^b   Jang, Myoung Kuk ^c   Cho, Eun Young ^d   Shin, Eun Soon ^d   Lee, Jong Eun ^d   Park, Neung Hwa ^b   Yu, Eunsil ^b   Lee, Young Joo ^b  

^a Soonchunhyang University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

^d DNA Link Inc   (South Korea)

Author keywords

Angiogenesis; Hepatocellular carcinoma; MTA1; Polymorphism

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; CREATININE; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METASTATIC TUMOR ANTIGEN 1; SOMATOMEDIN B; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALLELE; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DISEASE SEVERITY; EXON; FEMALE; GENE FREQUENCY; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROTHROMBIN TIME; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HISTONE DEACETYLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE; REPRESSOR PROTEINS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863071925     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02648.x     Document Type: Article

References (39)

1. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-16.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
5. Valfrè di Bonzo L, Novo E, Cannito S, et al. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009; 24: 1323-41.
6. Mise M, Arii S, Higashituji H, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996; 23: 455-64.
7. Yamaguchi R, Yano H, Iemura A, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28: 68-77.
8. Pang R, Poon RTP. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006; 242: 151-67.
9. Amaoka N, Osada S, Kanematsu M, et al. Clinicopathological features of hepatocellular carcinoma evaluated by vascular endothelial growth factor expression. J Gastroenterol Hepatol 2007; 22: 2202-7.
10. Asahara T, Bauters C, Zheng LP, et al. Synegic effect of vascular endotherlial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92: II365-71.
11. García-Closas M, Malats N, Real FX, et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007; 3: e29.
12. Bradbury PA, Zhai R, Ma C, et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009; 15: 4680-5.
13. Hsiao PJ, Lu MY, Chiang FY, et al. Vascular endothelial growth factor gene polymorphisms in thyroid cancer. J Endocrinol 2007; 195: 265-70.
14. Guan X, Zhao H, Niu J, et al. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol 2009; 9: 77.
15. Kong SY, Park JW, Lee JA, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 2007; 46: 446-55.
16. Moon HE, Cheon H, Chun KH, et al. Metastasis-associated protein 1 enhances angiogenesis by stabilization of HIF-1alpha. Oncol Rep 2006; 16: 929-35.
17. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
18. Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1 alpha protein by recruiting histone deacetylase 1. EMBO J 2006; 25: 1231-41.
19. Toh Y, Pencil SD, Nicolson GL. A novel candidate metastasis associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression and protein analyses. J Biol Chem 1994; 269: 22958-63.
20. Hofer MD, Kuefer R, Varambally S, et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 2004; 64: 825-9.
21. Yoo YG, Na TY, Seo HW, et al. Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene 2008; 27: 3405-13.
22. Lee H, Ryu SH, Hong SS, et al. Overexpression of metastasis-associated protein 2 is associated with hepatocellular carcinoma size and differentiation. J Gastroenterol Hepatol 2009; 24: 1445-50.
23. Hamatsu T, Rikimaru T, Yamashita Y, et al. The role of MTA1 gene expression in human hepatocellular carcinoma. Oncol Rep 2003; 10: 599-604.
24. Moon WS, Chang K, Tarnawski AS. Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-alpha. Hum Pathol 2004; 35: 424-9.
25. Ryu SH, Chung YH, Lee H, et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology 2008; 47: 929-36.
26. Yu JC, Hsu HM, Chen ST, et al. Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility. J Biomed Sci 2006; 13: 419-32.
27. Dahiya D, Wu TJ, Lee CF, et al. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery 2010; 147: 676-85.
28. Gu X, Qi P, Zhou F, et al. An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population. Hum Genet 2010; 127: 75-81.
29. Wang J, Xu Y, Xu Y, et al. Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 2008; 26: 359-68.
30. Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 2005; 42: 846-53.
31. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008; 267: 226-44.
32. Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003; 198: 1391-402.
33. Chang CC, Chen SC, Hsieh YH, et al. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med 2009; 47: 412-8.
34. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
35. von Marschall Z, Cramer T, Hocker M, et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 2001; 48: 87-96.
36. Wu LM, Xie HY, Zhou L, et al. A single nucleotide polymorphism in the vascular endothelial growth factor gene is associated with recurrence of hepatocellular carcinoma after transplantation. Arch Med Res 2009; 40: 565-70.
37. Oka Y, Waterland RA, Killian JK, et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 2002; 35: 1153-63.
38. De Souza AT, Hankins GR, Washington MK, et al. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995; 11: 447-9.
39. Chao W, D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008; 19: 111-20.